BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 32693197)

  • 1. Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve.
    Jawitz OK; Wang TY; Lopes RD; Chavez A; Boyer B; Kim H; Anstrom KJ; Becker RC; Blackstone E; Ruel M; Thourani VH; Puskas JD; Gerdisch MW; Johnston D; Capps S; Alexander JH; Svensson LG
    Am Heart J; 2020 Sep; 227():91-99. PubMed ID: 32693197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model.
    Lester PA; Coleman DM; Diaz JA; Jackson TO; Hawley AE; Mathues AR; Grant BT; Knabb RM; Ramacciotti E; Frost CE; Song Y; Wakefield TW; Myers DD
    Arterioscler Thromb Vasc Biol; 2017 May; 37(5):942-948. PubMed ID: 28232327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial.
    Guimarães PO; Pokorney SD; Lopes RD; Wojdyla DM; Gersh BJ; Giczewska A; Carnicelli A; Lewis BS; Hanna M; Wallentin L; Vinereanu D; Alexander JH; Granger CB
    Clin Cardiol; 2019 May; 42(5):568-571. PubMed ID: 30907005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.
    Kuwahara T; Abe M; Yamaki M; Fujieda H; Abe Y; Hashimoto K; Ishiba M; Sakai H; Hishikari K; Takigawa M; Okubo K; Takagi K; Tanaka Y; Nakajima J; Takahashi A
    J Cardiovasc Electrophysiol; 2016 May; 27(5):549-54. PubMed ID: 26766541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apixaban versus warfarin in patients with atrial fibrillation.
    Granger CB; Alexander JH; McMurray JJ; Lopes RD; Hylek EM; Hanna M; Al-Khalidi HR; Ansell J; Atar D; Avezum A; Bahit MC; Diaz R; Easton JD; Ezekowitz JA; Flaker G; Garcia D; Geraldes M; Gersh BJ; Golitsyn S; Goto S; Hermosillo AG; Hohnloser SH; Horowitz J; Mohan P; Jansky P; Lewis BS; Lopez-Sendon JL; Pais P; Parkhomenko A; Verheugt FW; Zhu J; Wallentin L;
    N Engl J Med; 2011 Sep; 365(11):981-92. PubMed ID: 21870978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of apixaban versus aspirin for the prevention of latent bioprosthetic aortic valve thrombosis: study protocol for a prospective randomized trial.
    Kopjar T; Gasparovic H; Paar MH; Lovric D; Cerina P; Tokic T; Milicic D
    Trials; 2024 May; 25(1):324. PubMed ID: 38755709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve.
    Wang TY; Svensson LG; Wen J; Vekstein A; Gerdisch M; Rao VU; Moront M; Johnston D; Lopes RD; Chavez A; Ruel M; Blackstone EH; Becker RC; Thourani V; Puskas J; Al-Khalidi HR; Cable DG; Elefteriades JA; Pochettino A; Wolfe JA; Graeve A; Sultan I; Sabe AA; Michelena HI; Alexander JH
    NEJM Evid; 2023 Jul; 2(7):EVIDoa2300067. PubMed ID: 38320162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
    Lopes RD; Alexander JH; Al-Khatib SM; Ansell J; Diaz R; Easton JD; Gersh BJ; Granger CB; Hanna M; Horowitz J; Hylek EM; McMurray JJ; Verheugt FW; Wallentin L;
    Am Heart J; 2010 Mar; 159(3):331-9. PubMed ID: 20211292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study).
    Nakamura M; Nishikawa M; Komuro I; Kitajima I; Uetsuka Y; Yamagami T; Minamiguchi H; Yoshimatsu R; Tanabe K; Matsuoka N; Kanmuri K; Ogawa H
    Circ J; 2015; 79(6):1230-6. PubMed ID: 25912695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.
    Hohnloser SH; Fudim M; Alexander JH; Wojdyla DM; Ezekowitz JA; Hanna M; Atar D; Hijazi Z; Bahit MC; Al-Khatib SM; Lopez-Sendon JL; Wallentin L; Granger CB; Lopes RD
    Circulation; 2019 May; 139(20):2292-2300. PubMed ID: 30773022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of a randomized trial of apixaban vs warfarin to evaluate atherosclerotic calcification and vulnerable plaque progression.
    Osawa K; Nakanishi R; Win TT; Li D; Rahmani S; Nezarat N; Sheidaee N; Budoff MJ
    Clin Cardiol; 2017 Oct; 40(10):807-813. PubMed ID: 28703931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
    Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
    Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial.
    Al-Khatib SM; Mulder H; Wojdyla D; Lopes RD; Wallentin L; Alexander JH; Hijazi Z; Goto S; Granger CB
    Circ Arrhythm Electrophysiol; 2021 Mar; 14(3):e009614. PubMed ID: 33657831
    [No Abstract]   [Full Text] [Related]  

  • 15. Anticoagulation and Antiplatelet Strategies After On-X Mechanical Aortic Valve Replacement.
    Puskas JD; Gerdisch M; Nichols D; Fermin L; Rhenman B; Kapoor D; Copeland J; Quinn R; Hughes GC; Azar H; McGrath M; Wait M; Kong B; Martin T; Douville EC; Meyer S; Ye J; Jamieson WRE; Landvater L; Hagberg R; Trotter T; Armitage J; Askew J; Accola K; Levy P; Duncan D; Yanagawa B; Ely J; Graeve A;
    J Am Coll Cardiol; 2018 Jun; 71(24):2717-2726. PubMed ID: 29903344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.
    Lassen MR; Davidson BL; Gallus A; Pineo G; Ansell J; Deitchman D
    J Thromb Haemost; 2007 Dec; 5(12):2368-75. PubMed ID: 17868430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and Rationale for the Direct Oral Anticoagulant Apixaban in Left Ventricular Assist Devices (DOAC LVAD) Study.
    Dimond M; Looby M; Shah B; Sinha SS; Isseh I; Rollins AT; Abdul-Aziz AA; Kennedy J; Tang DG; Klein KM; Casselman S; Vermeulen C; Sheaffer W; Snipes M; O'connor CM; Shah P
    J Card Fail; 2024 Jun; 30(6):819-828. PubMed ID: 37956897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin After Bioprosthetic Valve Replacements.
    Pasciolla S; Zizza LF; Le T; Wright K
    Clin Drug Investig; 2020 Sep; 40(9):839-845. PubMed ID: 32607688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
    Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
    Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.